Please login to the form below
sitagliptin
This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option
In the programme, Rybelsus was shown to more effectively lower blood sugar than sitagliptin and empagliflozin, and treatment with Rybelsus also resulted in up to 4.4kg reduction in body weight.
Latest news
-
Givlaari, Rybelsus lead crowded CHMP recommendations
In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved greater blood glucose reductions compared to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), Boehringer Ingelheim and Eli
-
Merck CFO: we’re not only about Keytruda
shrug off a 12% decline for diabetes treatment Januvia (sitagliptin) on pricing pressure.
-
Novo Nordisk gets FDA okay for new diabetes hope
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's DPP-4 inhibitor Januvia(sitagliptin), Boehringer Ingelheim and Eli Lilly's SGLT2
-
Novo uses voucher for speedy answer on oral semaglutide
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's Januvia (sitagliptin) Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) and
-
Analysts look beyond Keytruda in Merck’s future
Chief executive Ken Frazier took pains to point to other growth spots in MSD’s portfolio, particularly as diabetes blockbuster Januvia (sitagliptin) showed signs of weakness again after a return to
More from news
Approximately 8 fully matching, plus 89 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
-
Interview: Christopher Boulton, AstraZeneca
sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Fishawack Health
Established in 2001, Fishawack Health (FH) is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries....
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
